BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J 2020;8:91-8. [PMID: 32213052 DOI: 10.1177/2050640619895361] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Segal JP, Quraishi MN. Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis. United European Gastroenterol J 2021;9:127. [PMID: 33176618 DOI: 10.1177/2050640620972959] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
3 Venkateswaran N, Weismiller S, Clarke K. Indeterminate Colitis - Update on Treatment Options. J Inflamm Res 2021;14:6383-95. [PMID: 34876831 DOI: 10.2147/JIR.S268262] [Reference Citation Analysis]
4 Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet J, Nahon S, Bouguen G, Viennot S, Pariente B, Fumery M; UC-USK-GETAID Study Group. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther 2020;51:1039-46. [DOI: 10.1111/apt.15717] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
5 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Reference Citation Analysis]
6 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
7 McDonald BD, Dyer EC, Rubin DT. IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis 2022;16:ii42-53. [PMID: 35553664 DOI: 10.1093/ecco-jcc/jjac038] [Reference Citation Analysis]
8 Segal JP, Quraishi MN. Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis. United European Gastroenterol J 2021;9:279. [PMID: 33871925 DOI: 10.1002/ueg2.12052] [Reference Citation Analysis]
9 Ladrón Abia P, Minguez Sabater A, Sáez González E, Beltrán Niclós B. Rescue therapy with oral cyclosporine after use of ustekinumab in ulcerative colitis resistant to multiple treatments. Gastroenterol Hepatol 2021:S0210-5705(21)00170-9. [PMID: 34082044 DOI: 10.1016/j.gastrohep.2021.04.012] [Reference Citation Analysis]
10 Chiappetta MF, Viola A, Mastronardi M, Turchini L, Carparelli S, Orlando A, Biscaglia G, Miranda A, Guida L, Costantino G, Scaldaferri F, Bossa F, Renna S, Cappello M, Alibrandi A, Orlando A, Armuzzi A, Fries W. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther 2021;:1-7. [PMID: 34521307 DOI: 10.1080/14712598.2021.1981855] [Reference Citation Analysis]
11 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Chaparro M, Garre A, Iborra M, Sierra M, Barreiro-de Acosta M, Fernández-Clotet A, de Castro L, Boscá-Watts M, Casanova MJ, López-García A, Lorente R, Rodríguez C, Carbajo AY, Arroyo MT, Gutiérrez A, Hinojosa J, Martínez-Pérez T, Villoria A, Bermejo F, Busquets D, Camps B, Cañete F, Manceñido N, Monfort D, Navarro-Llavat M, Pérez-Calle JL, Ramos L, Rivero M, Angueira T, Camo P, Carpio D, García-de-la-Filia I, González-Muñoza C, Hernández L, Huguet JM, Morales VJ, Sicilia B, Vega P, Vera I, Zabana Y, Nos P, Suárez Álvarez P, Calviño-Suarez C, Ricart E, Hernández V, Mínguez M, Márquez L, Hervías Cruz D, Rubio Iturria S, Barrio J, Gargayo-Puyuelo C, Francés R, Hinojosa E, Del Moral M, Calvet X, Algaba A, Aldeguer X, Guardiola J, Mañosa M, Pajares R, Piqueras M, García-Bosch O, Lopez Serrano P, Castro B, Lucendo AJ, Montoro M, Castro Ortiz E, Mesonero F, García-Planella E, Fuentes DA, Bort I, Delgado-Guillena P, Arias L, Iglesias A, Calvo M, Esteve M, Domènech E, Gisbert JP. Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry. J Crohns Colitis 2021:jjab070. [PMID: 33860795 DOI: 10.1093/ecco-jcc/jjab070] [Reference Citation Analysis]